Eledon Pharmaceuticals, Inc.

**Signal Note: BVF Partners Entry into ELDN** BVF's $9.5M initiation in Eledon signals conviction in EL-325 (anti-CD40L monoclonal antibody) for transplant rejection, a high-unmet-need indication with clear regulatory pathways and potential peak sales >$500M if successful. The timing likely reflects upcoming Phase 2b data or FDA interactions for kidney transplant, where CD40L blockade has shown durable graft survival benefits in early studies. This represents a classic Lampert play—overlooked asset in immunology with binary catalysts over the next 12-24 months.